Summary A rapid, functional and quantitative diagnostic method for the estimation of the P-glycoprotein (Pgp)-dependent multidrug resistance is required in the clinical treatment of human tumours, as chemotherapy protocols and resistance-reversing agents could be applied accordingly. In the present work, by using a calcein accumulation method in combination with immunorecognition and drug-resistance studies, a new method is described for the quantitative estimation of the expression and function of the multidrug transporter. MDR1-transfected and drug-selected tumour cell lines with various levels of drug resistance were examined. The expression of P-gp and its cell-surface appearance were assessed by quantitative immunoblotting and by immunofluorescence cytometry. The transport function of the P-gp was assessed by measuring the extrusion of calcein acetoxymethyl ester (AM) with fluorometry and flow cytometry, while in parallel experiments drug resistance was directly examined in cell survival assays. The MDR1 activity factor (MAF), calculated from the calcein AM extrusion assay, is demonstrated to provide a reliable quantitative measure for MDR1 specific activity, reflecting cellular drug resistance. This relatively simple and rapid new functional P-gp assay surpasses the formerly used techniques in both sensitivity and reproducibility.
Ineffectiveness of tumour chemotherapy is often caused by the resistance of malignant cells to a wide range of hydrophobic cytostatic agents. The main characteristic of these multidrug-resistant cells is an energy-dependent outward transport of drugs by a membrane glycoprotein, identified as P-gp [multidrug resistance protein (MDRl), multidrug transporter]. Another key feature of multidrug resistance is its potential reversibility by a great variety of agents, such as verapamil, quinidine, calmodulin inhibitors, phenothiazines, reserpine or cyclosporin A ).
Reliable estimation of the level of multidrug resistance in tumour cells would be extremely important in the clinical treatment of various cancerous diseases, as combination chemotherapy treatment protocols could be adjusted and drug-resistance reversing agents could be applied accordingly. However, current laboratory methods are mostly restricted to the estimation of expression and/or surface appearance of P-gp and are less suitable for a parallel and quantitative estimation of the expression and function of this drug transporter.
The P-gp function can be followed by measuring the cellular uptake, efflux or steady-state distribution of several fluorescent MDR1 substrates, e.g. anthracyclines (Herweijer et al., 1989) , verapamil derivatives (Lelong et al., 1991) , rhodamine 123 (Neyfakh, 1988; Chaudhary and Roninson, 1991); and Fluo-3 (Wall et al., 1991, 1993) , SY-38 and SY-3150 (Frey et al., 1995) respectively. However, these fluorescence assays have serious drawbacks in quantification. The fluorescence and the cellular distribution of these compounds are dependent on pH, and the alteration of intracellular pH depending on MDR1 expression has been reported (Thiebaut et al., 1990; Roepe, 1992; Roepe et al., 1993) . In the case of Fluo-3, changes in intracellular free calcium significantly alter the fluorescence of this calcium indicator dye.
Fluorescence drug uptake measurements require relatively long incubation periods (30-60 (Herweijer et al., 1989) . The fluorescence of anthracyclines is quenched upon binding to DNA and/or cellular components (Roepe, 1992; Goldstein et al., 1992) , therefore the determination of their intracellular concentrations is uncertain. In addition, the initial anthracycline efflux rate (Roepe, 1992) , as well as the fast component of the efflux rate of coumarin-conjugated vinblastine (Bornmann and Roepe, 1994) was found to be independent from the amount of expressed MDR1 over a wide range of drug concentrations. A more accurate determination of MDR1 activity can be achieved by using a flow-through system, although a sophisticated kinetic analysis is required for quantitative evaluation (Spolestra et al., 1992) .
The fluorescence assay method most commonly used to discriminate between drug-resistant and -sensitive cells is based on the efflux of rhodamine 123, and a correlation of MDR1-mediated rhodamine 123 efflux with mdrl mRNA levels has been reported (Lee et al., 1994) . Although the sensitivity of this method is higher than that of the fluorescent anthracycline measurements, the proper quantification of the transport activity is hindered by a non-MDR1-mediated efflux and by non-specific changes in rhodamine 123 fluorescence. This dye exhibits relatively poor cellular retention, which strongly depends on the cell type, and interacts with various intracellular compartments and organelles (e.g. mitochondria), producing a spectral shift and a change in fluorescence intensity (Weaver et al., 1991) . In addition, the rhodamine 123 efflux measurement raises several technical problems: (i) initial dye concentrations are diverse in different cell types (Lee et al., 1994) ; (ii) the concentration of the transported substance changes during the measurement. The determination of the efflux rate constants from an exponential fluorescence decay may overcome these problems, but at high loading levels-when the transporter tends to be saturated with the dye -no exponential decay was found (Altenberg et al., 1994) . It has also to be noted that for rhodamine efflux measurements cells have to be incubated for 1-2 h (Lee et al., 1994; Mechetner and Roninson, 1992) , or even 3-10 h in clinical samples (Chaudhary and Roninson, 1991) in a dye free medium after a usual 30 min loading procedure.
We have formerly demonstrated that the hydrophobic acetoxymethyl ester (AM) derivatives of various fluorescent 850
indicators (Homolya et al., 1993) , and calcein accumulation is prevented in mouse fibroblasts transfected with human MDR1 (Hollo et al., 1994 (Haughland and Larison, 1992) . The most favourable property of this assay method, based on AM extrusion, is that the detected compound is different from the transported one. Thus, a steady-state level of the MDR1-transported substrate is detected by a coupled enzymatic reaction (i.e. esterase cleavage). Owing to enzymatic enhancement of the dyetrapping process, the sensitivity of this assay highly surpasses that of the formerly used methods. The Fluo-3 accumulation provided a 7-fold higher signal than doxorubicin accumulation measurements (Wall et al., 1991) . Owing to the higher affinity of calcein AM to MDR1, as compared with that of Fluo-3 AM (Homolya et al., 1993) , the sensitivity of the calcein assay is even higher (2.5-fold) than that of the Fluo-3 accumulation method, while avoiding the possible effects of changes in cellular free calcium.
In the present paper we describe the parallel measurements of several morphological and functional characteristics of Pgp in various multidrug-resistant human and mouse cell lines, and provide an approach for the quantitative estimation of the expression and function of this drug extrusion protein. Gibco/Life Technologies (Gaithersburg, MD, USA), and supplemented with 10% fetal bovine serum (Sebak, Aidenbach, Germany), 5 mM glutamine, 100 units ml-' penicillin and 100 pg ml-' streptomycin (Sigma Chemical , St. Louis, MO, USA). Drug-selected cell lines were reselected by culturing for 3 days in standard media containing cytostatic agents. P388 and K562 cells were grown in media containing 50 ng ml-' and 100 ng ml-' doxorubicin (Sigma) respectively. KB-V1 cells were cultured in media containing 500 ng ml-' vincristine (Eli Lilly, Indianapolis, IN, USA). In order to achieve different levels of drug resistance the selection procedure was repeated several times.
Recombinant baculovirus carrying the human MDR1 gene was generated, and the Sf9 (Spodoptera frugiperda) cells were infected by the MDR1 baculovirus and cultured according to the procedures described previously .
Separation of mononuclear cells of leukaemia patients Freshly drawn peripheral blood of leukaemia patients was diluted with an equal volume of HPMI medium (Homolya et al., 1993) and overlaid on Ficoll-Histopaque-1077 (Sigma). The suspension was centrifuged at 1500 g for 15 min at room temperature, the mononuclear cell-containing interface was transferred to another tube, diluted with excess HPMI medium, washed twice and finally resuspended in HPMI medium.
Quantitative immunoblotting Electrophoresis and immunoblotting with the 4077 polyclonal antibody, which recognises both mouse and human MDR1 (Tanaka et al., 1990) , were carried out as described in Sarkadi et al. (1992) Figure  1 , with any other cellular protein. The immunoreactive bands in Figure 1 This difference is even larger in the excessively drug-selected P388b cells, in good correlation with the amount of the expressed MDR1 protein (see Figure lb) .
As shown in Figure 2 , the slopes of fluorometric curves are identical after the addition of verapamil, suggesting that the reversal of reduced calcein accumulation was complete and the applied concentration of verapamil did not modify the cellular esterase activity. Although the affinity of calcein AM to P-gp is higher than that of verapamil, a 10-fold excess of the reversing agent was sufficient for complete blocking of calcein AM extrusion (see Homolya et al., 1993) . In order to ensure a quantitative evaluation, the highest concentration of verapamil (but still without non-specific effect on the membrane permeability and/or cellular esterase activity) was applied in these and the following experiments and we found that calcein accumulation in the various control cell lines was not affected by verapamil up to a concentration of 150 gM. Figure 1 and below) . Since the plasma membrane insertion of the MDRl is required for its drug-extrusion activity, in parallel flow cytometry measurements we have determined the cell-surface expression and the pumping activity of P-gp. For immunofluorescence labelling the UIC2 monoclonal antibody was applied, which reacts exclusively with extracellular epitope(s) of human P-gp (Mechetner and Roninson, 1992) . As demonstrated in Figure 3a , the cell surface labelling by UIC2 is in accordance with the immunoblot data (see Figure  la) . The immunofluorescence labelling was compared with the labelling with an IgG, isotype control, indicated as an outline. In similar experiments the MDR1 cell-surface expression was determined in several cell lines expressing human P-gp (see below), and a linear correlation was found between UIC2 binding and MDR1 levels measured by quantitative immunoblotting (r = 0.970, P = 1.6 x 10 7). Figure 3b demonstrates the flow cytometry measurements of calcein accumulation in the same series of KB cells as shown in Figure 3a . The cells were incubated for 10 min with calcein AM in the absence and presence of verapamil respectively. As demonstrated, calcein accumulation showed a mirror image of the cell-surface labelling by UIC2, that is the more P-gp was expressed, the lower level of calcein fluorescence was detected. Verapamil restored calcein accumulation to the control level. The sensitivity of the assay in most cases remarkably surpassed that of the cell surface labelling, but both measurements reflected the relative doxorubicin resistance in these different MDR1-expressing KB cells (see the legend to Figure 1) .
Since the decrease in dye uptake rate correlates both with MDR1 expression and drug resistance, the calcein assay may provide an opportunity for quantitative determination of the MDR1 function. If dye extrusion is entirely blocked by verapamil, the difference between the dye uptake rates after and before verapamil addition respectively, reflects the pumping activity of the multidrug transporter. In order to eliminate the errors arising from differences in esterase activity, cell volume and other fluctuations in the experimental conditions (e.g. cell number, dye concentration, parameters of the fluorescence equipment, etc.), the difference was normalised to an internal standard, provided by the dye uptake rate after the addition of verapamil. Thus, MDR1 activity was expressed by the following dimensionless empirical paramater: MDR1 activity factor: MAF = (F* -F)/F*
where F* and F designate the dye accumulation rates in the presence and absence of an MDR1 inhibitor respectively. We have examined the appropriate conditions for calcein assay in great detail, and found that at pH values in the media between 7.0 and 7.8, at calcein AM concentrations between 0.1 and 1 gM and at cell numbers between 5 x 104 ml-' and 2 x 106 ml -, the value of the MDR1 activity factor remained practically unchanged. Free calcein leakage was found to be extremely slow, its half-time being over 5 h at 25 and 37°C, both in the control and the MDRl-expressing cells. We have also examined the effects of various inhibitors of MDR1 (e.g. vinblastine, vanadate, cyclosporin A) for calcein accumulation (see Hollo et al., 1994) , and found that whenever maximum inhibition was achieved, the nature of inhibition (competitive or non-competitive) did not influence the obtained MAF value. In addition to the complete blocking of calcein AM extrusion, the important features of the MDR1 inhibitor applied in this test should be, that in the concentrations used:
(i) it should not interfere with the fluorescence of calcein; (ii) it should not inhibit cellular esterase activity; (iii) it should not change the non-specific membrane permeability for calcein. expression was quantitatively assessed by Western blotting by using the 4077 polyclonal antibody and the HRP/ECL luminescence method. The MDR1 activity factor (MAF) was calculated for each cell line by using the calcein accumulation rates determined before and after verapamil addition from the fluorometric time courses, as shown in Figure 2 , and by using equation (1) Figure   3 . The MAF values were calculated from the absolute fluorescence obtained in the absence and presence of verapamil, and by using equation (1) ting (see Figure 1 ), while Figure 4b shows Figure 5 . The cellsurface expression of P-gp was detected by UIC2 (Figure 5a) , indicating a 1.15 times increase in labelling, as compared with the isotype control. In a parallel experiment the calcein accumulation assay in the same sample (Figure 5b) showed a clear measurable difference in the absence and presence of verapamil respectively, yielding a MAF of 0.31. According to our preliminary data obtained with leucocyte samples of haematological patients, the clinically drug-resistant cells show relatively low MDR1 expression, and are in the MAF = 0.05-0.5 range. As indicated by Figure 4 , this is the range where the MAF is proportional to P-gp expression and the sensitivity of the method is the highest.
The 
